Matrixx Projects Profit, But Zicam Litigation "Storm Clouds" Could Still Rain
This article was originally published in The Tan Sheet
Executive Summary
Matrixx Initiatives believes it has emerged with a plan for returning to growth and profitability after navigating the gauntlet of an FDA warning, product recall and millions in lost revenue in fiscal 2010
You may also be interested in...
Matrixx Prompts Supreme Court To Consider What Firms Must Disclose
A class action suit against Zicam Cold Remedy maker Matrixx Initiatives heads to the Supreme Court, in a case that could affect the number of securities actions brought against pharma companies
NACDS Marketplace In Brief
Matrixx prepares to launch cold products: Matrixx Initiatives prepares to launch two oral Zicam Cold Remedy products in July and August, CEO Bill Hemelt said at the National Association of Chain Drugstores Marketplace conference and trade show in San Diego June 5-8 (1"The Tan Sheet" May 17, 2010). The products are in the Cold Remedy Plus line - an oral mist and a rapid melt. The suggested retail price for the products is $11.99, he said
Zicam Swab Platform Takes Center Stage In Matrixx Growth Plans
Matrixx Initiatives plans to introduce more products delivered via the swab platform used in one of the Zicam nasal products that FDA advised the firm to recall in 2009